iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · Real-Time Price · USD
10.12
+0.01 (0.05%)
Aug 15, 2025, 9:42 AM - Market open
iTeos Therapeutics Revenue
In the year 2024, iTeos Therapeutics had annual revenue of $35.00M with 177.89% growth.
Revenue (ttm)
$35.00M
Revenue Growth
+177.89%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
173
Market Cap
447.14M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ITOS News
- 23 days ago - ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS - Business Wire
- 24 days ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc. - PRNewsWire
- 25 days ago - iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right - GlobeNewsWire
- 2 months ago - iTeos Therapeutics Announces Its Intention to Wind Down Operations - GlobeNewsWire
- 3 months ago - iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - GlobeNewsWire
- 3 months ago - iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 months ago - iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - GlobeNewsWire
- 5 months ago - iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire